The impact of seat height on 1-min sit-to-stand test performance in COPD: a randomised crossover trial

Valerie Zumbrunnen1,2, Thomas F. Riegler1,3, Sarah R. Haile4 and Thomas Radtke4

1Berner Reha Zentrum AG, Heiligenschwendi, Switzerland. 2Department of Health Professions, Bern University of Applied Science, Bern, Switzerland. 3Institute for Physiotherapy, Zurich University of Applied Science, Zurich, Switzerland. 4Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Corresponding author: Valerie Zumbrunnen (v@zumbrunnen.be)

Shareable abstract (@ERSpublications)
Performing the 1MSTS test on an individually adjusted chair versus a standard chair results in fewer repetitions (mean difference $-0.78$, 95% CI $-1.47$ to $-0.11$). However, the difference in repetitions is clinically negligible. https://bit.ly/3Oc8Rvp

Cite this article as: Zumbrunnen V, Riegler TF, Haile SR, et al. The impact of seat height on 1-min sit-to-stand test performance in COPD: a randomised crossover trial. ERJ Open Res 2022; 8: 00033-2022 [DOI: 10.1183/23120541.00033-2022].

Abstract

Study question Is there a difference in the number of repetitions in the 1-minute sit-to-stand (1MSTS) test using an individually adapted seat height to 90° knee flexion (1MSTSIND), compared with the commonly used standard chair seat height of 46 cm (1MSTSTD), in people with COPD?

Methods We conducted a single-centre, single-blinded, randomised crossover trial in people with COPD between August 2020 and March 2021 at a specialised rehabilitation clinic in Switzerland. After a learning 1MSTS test, all participants performed two 1MSTS tests in random order on consecutive days. Participants were blinded, as they did not receive detailed information on the testing protocols.

Results 49 individuals with COPD (47% female) participated. In a regression model adjusted for sequence period and subject, 1MSTS test performance was lower on 1MSTSIND compared to 1MSTSTD ($-0.78$ repetitions, 95% CI $-1.47$ to $-0.11$). In a second regression model additionally including the knee angle and an interaction term (1MSTSIND×knee angle), the interaction term was significant: 0.18 (95% CI 0.05 to 0.30). The limits of agreement were between $-5.5$ and $4$ repetitions.

Conclusion Although we observed a statistically significant difference between 1MSTSIND and 1MSTSTD on a population level, the difference is negligible. Further studies may be needed to determine whether individual adaptation of seat height is needed for very tall or short people to ensure a valid assessment of 1MSTS test performance in COPD.

Introduction

Evaluation of functional exercise capacity of people with COPD is a cornerstone of pulmonary rehabilitation programmes [1]. In recent years, the 1-min sit-to-stand (1MSTS) test has gained increasing interest among clinicians and researchers [2, 3]. It is a simple, valid, reliable and responsive exercise test in people with COPD [4], and a strong predictor of 2-year mortality [5].

The 1MSTS is commonly performed using a chair with a seat height of 46–48 cm [4–10]. However, using a standard seat height for all individuals – irrespective of their body height – may lead to invalid estimates of functional exercise capacity. Taller people are potentially disadvantaged, because they need to cover a greater distance during the sit-to-stand (STS) movement, whereas shorter people may have an advantage resulting in better performance [11–14]. Previous work on determinants of STS performance revealed that seat height (among other factors such as the use of armrests and foot position) influence STS performance [12, 15, 16]. In elderly people, seat heights between 80 and 120% of an individual’s leg length revealed a tendency towards reduced quickness and force production in the phases of trunk flexion and knee and hip joint extension [16], suggesting that individual adaptation of seat height is necessary when performing STS tests [12, 16].

https://doi.org/10.1183/23120541.00033-2022
To date, the impact of an individually adjusted seat height versus standard seat height on 1MSTS test performance in COPD is unknown. This study aimed to evaluate the impact of an individually adapted seat height to 90° knee flexion (1MSTS\textsubscript{IND}) compared to the commonly used seat height of 46 cm (1MSTS\textsubscript{STD}) on 1MSTS test performance in people with COPD.

We hypothesised that taller people perform more STS repetitions when performing the test on a higher 1MSTS\textsubscript{IND} than on the lower 1MSTS\textsubscript{STD}, whereas shorter people perform fewer STS repetitions on 1MSTS\textsubscript{IND} than on the higher 1MSTS\textsubscript{STD}.

**Methods**

**Study subjects**

Participants were recruited at the Berner Reha Zentrum AG in Bern, Switzerland. They were included in this study if they had a diagnosis of COPD and a forced expiratory volume in 1 s (FEV\textsubscript{1}) / forced vital capacity (FVC) ratio below the lower limit of normal [17, 18]. We excluded participants who 1) were not able to bend their knee at least 90° while sitting on a standard chair; 2) did not understand the test instructions, either because of language or for cognitive reasons; 3) were unable to perform the 1MSTS test due to functional disability (i.e. not being able to stand up from a chair without hand support); 4) had a previous surgery or reported pain that would interfere with the performance of the 1MSTS, as judged by the responsible physician. All participants provided written informed consent, after they were given at least 24 h to decide [19]. The recruitment was performed consecutively between August 2020 and March 2021. The study protocol was approved by the Cantonal Ethics Committee Bern (BASEC-ID 2020-01677), and the study was registered at www.ClinicalTrials.gov (NCT04579055).

**Study design**

We conducted a single-centre, single-blinded, randomised crossover trial. All assessments were performed during the inpatient pulmonary rehabilitation and were carried out by the same investigator.

First, a 1MSTS familiarisation test (1MSTS\textsubscript{TEST}) was performed, followed by the randomisation process. Participants were not informed about the randomisation result, and they did not receive any further information about the testing protocol. After randomisation, each participant performed two 1MSTS tests in random order on two consecutive days at the same time of day. We scheduled the study visits to ensure that the participants had at least 1 h rest before the examination.

**Randomisation and masking**

A computer-generated list of random numbers was created by an external biostatistician using the R package “blockrand” [20] and implemented into the database by a person who was not involved in the recruitment process. The randomisation of chair order (1MSTS\textsubscript{STD} then 1MSTS\textsubscript{IND}, or vice versa) was stratified by type of seat height adjustment: 1) lower seat height (knee angle <89°), 2) standard seat height (knee angle 89–91°) or 3) higher individual seat height (knee angle >91°). Randomisation was performed within REDCap (Research Electronic Data Capture, Vanderbilt University, USA) [21], hosted by Berner Reha Zentrum AG. We were able to mask participants because the investigator prepared the chair height for the 1MSTS tests before the study visits.

**Measurements and test procedure**

**Leg length**

Leg length, defined as the length from the great trochanter of the femur to the malleolus lateralis, was measured while the participant was lying in a supine position [22]. Length of the lower leg, defined as the distance from the floor to the top of the fibula head, was measured while the participant was in a sitting position where the lower leg was placed vertically to the floor.

**Adjustment of seat height**

During the 1MSTS\textsubscript{TEST}, participants were asked to sit down with the buttock in the middle of the standardised chair. The lower leg was placed in a vertical position with a 90° angle construction (floor to lower leg). The knee flexion angle was measured with the Easy Angle Digital Goniometer (Meloq, Sweden) [23] using a standardised lever from the trochanter major to the knee joint (figure 1). Depending on the knee flexion angle of the participant sitting on the standard chair, the seat height of the chair was adjusted, aiming to ensure a 90° knee flexion.
1MSTS test and additional assessments
The aim of the 1MSTS test is to perform as many STS repetitions as possible in 1 min [2, 4, 5]. We used a height-adjustable chair (Embru, Switzerland) without an armrest, stabilised against the wall. We only counted correctly performed STS repetitions.

We performed all 1MSTS tests on a chair with an individually adjusted seat height (90° knee flexion when sitting on the chair). Before each 1MSTS test, participants received standardised instructions [4] that did not include information about seat height. In this way, participants were blinded to the experimental condition. Before, immediately after, and for 1 min after completing each test, we monitored heart rate and oxygen saturation (SpO₂) with a handheld pulse oximeter (Covidien Nellcor PM10N, Dublin, Ireland). At the same time points, we assessed ratings of perceived exertion and dyspnoea using a 0–10 Borg scale [24]. If participants needed oxygen while performing the tests, the same amount of oxygen was delivered for each test.

After completing the 1MSTS tests, subjects filled out a self-administered questionnaire. Questions evaluated understanding of the test instructions, the preferred sitting position on the chair, preferred change in seat height compared with the chair set-up that was used in the prior test condition and perceived difficulties during the test. The questionnaire was completed by each participant without asking the participant about the seat height (see online supplementary material).

Analysis
The primary outcome was analysed using two linear regression models. The first model (Model 1) focused on the difference in 1MSTS performance adjusting for the experimental condition (1MSTSSTD versus 1MSTSEND), period and subject [25]. This was based on our initial hypothesis and the assumption that taller people might be disadvantaged (and vice versa for shorter people) when performing the 1MSTS on a standard chair (1MSTSSTD). We assumed no difference in 1MSTS performance between the two experimental conditions on a population level, challenging the interpretation of the mean difference and 95% confidence intervals (CI). To account for that, we set up a second regression model (Model 2), in which we adjusted for experimental condition (1MSTSSTD versus 1MSTSEND), knee angle, the interaction of experimental condition and knee angle, period and subject. A significant chair times angle interaction would indicate that shorter people have advantages and taller people have disadvantages of different magnitudes with the different chairs.

To further explore the differences between the two experimental conditions, we used Bland–Altman plots to visually assess agreement in number of 1MSTS repetitions [26]. Such plots show average agreement (should be reasonably close to 0) and limits of agreement (gives a range of differences between the two conditions within which 95% of the observations fall). Additionally, we considered Bland–Altman plots adjusted for knee angle [27].

FIGURE 1 Measurement of knee flexion angle: a) start position with vertical position of lower leg, b) measurement of knee angle on the standard chair with 46 cm seat height, c) measurement of knee flexion angle of 90° after chair adjustment.
Secondary outcomes were the STS power index (STS\textsubscript{POWER}) [22], post-test heart rate, nadir Sp\textsubscript{O}2, perceived leg exertion and dyspnoea, and the number of incorrectly performed 1MSTS repetitions (e.g. legs were not fully straight during standing phase, or the chair was not touched with the buttock, or arms were used to support movement). All secondary outcomes were analysed with Models 1 and 2, except the number of incorrectly performed repetitions that were analysed qualitatively, and the self-administered questionnaire was analysed descriptively (n, %).

Sample size calculations were done using simulations in the R-Project, Version 4.0.3, www.r-project.org. Based on previous research from our group [4] we knew that repeated 1MSTS tests are highly correlated in people with COPD (r=0.95), and that we could expect a SD of about 6.3 for 1MSTS repetitions. With 33 participants, we estimated to have 80% power to detect a difference of 2 in the interaction term of the model including type of chair, knee angle, and the interaction between type of chair and knee angle. Additionally, based on the distribution of body height in our typical COPD population entering pulmonary rehabilitation (i.e. data were available from clinical charts), we expected fewer participants needing a higher seat height than the standard seat height. To account for this, we planned to extend recruitment until there were at least ten participants in this group. We planned to stop recruitment after inclusion of a total of 60 study participants, irrespective of the three group sizes.

The statistical analysis was performed using the R-Project, Version 4.0.3, www.r-project.org.

**Results**

55 participants were included in the study. Six participants were excluded from the analyses due to screening failures (n=3) and health issues (n=3), leaving 49 participants for the final analysis (table 1, figure 2).

In the allocated experiments requiring individual adjustment of seat height, 28 were tested on a lower seat height, and 10 participants were tested on a higher seat height than the standard chair. For the remaining 11 participants no seat height adjustment was necessary (i.e. knee angle on the standard chair was between 89° and 91°), and they performed both tests on the standard chair.

| TABLE 1 Participant characteristics |
|------------------------------------|
| Variables                           | Total sample size | 1MSTS\textsubscript{STD}–1MSTS\textsubscript{IND} | 1MSTS\textsubscript{IND}–1MSTS\textsubscript{STD} |
| Number of participants              | 49               | 24                               | 25                               |
| Age (years)                        | 68.8±9.2         | 66.7±9.7                         | 70.8±8.4                         |
| Sex (n, %)                         |                  |                                 |                                  |
| Female                             | 23 (47)          | 14 (58)                          | 9 (36)                           |
| Male                               | 26 (53)          | 10 (42)                          | 16 (64)                          |
| BMI (kg·m\textsuperscript{-2})     | 24.4±6.6         | 25.1±7.07                        | 23.72±6.18                      |
| Body height (cm)                   | 167±8            | 167±8                            | 168±9                            |
| FEV\textsubscript{1}/FVC (z-score) | -3.2±1.0         | -3.3±1.0                         | -3.0±1.1                         |
| FEV\textsubscript{1} (% predicted) | 43±18            | 42±19                            | 44±17                            |
| GOLD stages (n, %)                 |                  |                                 |                                  |
| II                                 | 22 (45)          | 11 (46)                          | 11 (44)                          |
| III                                | 26 (53)          | 12 (50)                          | 14 (56)                          |
| IV                                 | 1 (2)            | 1 (4)                            | 0                                |
| Leg length (cm)                    | 85.5±4.7         | 85.9±4.5                         | 85.1±4.9                         |
| Lower leg length (cm)              | 46.6±3.0         | 46.7±3.1                         | 46.4±3.0                         |
| Knee joint angle on standard chair (°) | 87±5            | 87±5                            | 87±5                            |
| Seat height of individual chair (cm) | 44.5±2.8       | 44.1±3.3                        | 44.8±2.1                        |
| <89° (range)                      | 42.6 (37.5–44.9) | 41.9 (37.5–44.6)                 | 43.3 (38.8–44.9)                |
| 89°–91°                           | 46               | 46                               | 46                               |
| >91° (range)                      | 47.9 (46.5–50.1) | 48.3 (46.8–50.1)                 | 47.4 (46.5–48.2)                |
| Repetitions during 1MSTS\textsubscript{TEST} | 14±5            | 15±6                            | 13±5                            |

Data are presented as: mean±SD, number (percentage) or mean (range). 1MSTS: 1 min sit-to-stand; 1MSTS\textsubscript{STD}: 1 min sit-to-stand test performed on 46 cm height chair; 1MSTS\textsubscript{IND}: 1 min sit-to-stand test performed on chair adapted to 90° knee flexion; 1MSTS\textsubscript{TEST}: 1 min sit-to-stand test performed on chair adapted to 90° knee flexion used as familiarisation test; FEV\textsubscript{1}: forced expiratory volume in 1 s; FVC: forced vital capacity.
Assessed for eligibility (n=214)

Enrolment

Excluded (n=159)
- Not meeting inclusion criteria (n=120)
- Declined to participate (n=12)
- Other reasons (n=27)

1MSTS\textsubscript{TEST} (n=55)

Excluded (n=1)
- Reason: screening failure (n=1)

Randomised (n=54)
Stratified by:
1) Knee angle <89°; adjustment to lower seat
2) Knee angle 89–91°; no adjustment
3) Knee angle >91°; adjustment to higher seat

Allocation

Allocated to 1MSTS\textsubscript{STD} (n=26)
- Received allocated sequence (n=25)
- Reason: back pain (n=1)

Allocated to 1MSTS\textsubscript{IND} (n=28)
- Received allocated sequence (n=26)
- Reason: screening failures (n=2)

Allocated to 1MSTS\textsubscript{STD} (n=26)
- Received allocated sequence (n=25)
- Reason: pectoralis major pain (n=1)

Allocated to 1MSTS\textsubscript{IND} (n=25)
- Received allocated sequence (n=24)
- Reason: nosebleed (n=1)

1 day washout phase

Analysis

Analysed (n=49)

FIGURE 2 Flow chart. 1MSTS\textsubscript{TEST}: 1-min sit-to-stand test, familiarisation test performed on individually adjusted chair; 1MSTS\textsubscript{STD}: 1-min sit-to-stand test performed on standard chair with a seat height of 46 cm; 1MSTS\textsubscript{IND}: 1-min sit-to-stand test performed on individually adjusted chair of 90° knee flexion.
Primary outcome: 1MSTS test performance

In Model 1, 1MSTS test performance was $-0.78$ repetitions (95% CI $-1.47$ to $-0.11$, $p=0.028$) lower with 1MSTSIND compared to 1MSTSSTD. In Model 2, the interaction term for experimental condition and knee angle was statistically significant: $0.18$ (95% CI $0.05$ to $0.30$, $p=0.008$) (table 2).

The mean difference in repetitions of the two experimental conditions in participants with a knee angle less than 89° was $-1.18$ (limits of agreement $-6.01$ to $3.65$) repetitions less on 1MSTSIND compared to 1MSTSSTD. The mean difference in repetitions in participants with a knee angle more than 91° was $0.8$ (limits of agreement $-4.24$ to $5.84$) repetitions more on 1MSTSIND compared to 1MSTSSTD. The mean difference in repetitions in participants with a knee angle of 89–91°, who performed the two 1MSTS tests on the standard chair, was $-1.27$ (limits of agreement $-4.68$ to $2.13$) (figure 3).

### TABLE 2  Mean differences between the two experimental conditions

| Outcomes                        | Model 1 (chair) | Model 2 (chair × angle) | Limits of agreement of mean differences |
|---------------------------------|-----------------|--------------------------|-----------------------------------------|
| STS repetitions (number)        | $-0.78$ (−1.47, −0.11) | $0.18$ (0.05, 0.30)     | $-5.5±3.9$                               |
| STS power index (Watts)         | $-0.05$ (−2.74, 2.64)  | $-0.23$ (−0.76, 0.30)   | $-19.8±19.6$                             |
| SpO2 nadir (%)                  | $-0.83$ (−1.79, 0.14)  | $0.06$ (−0.13, 0.25)    | $-7.6±5.9$                               |
| Heart rate (bpm)                | $1.33$ (−0.48, 3.09)   | $-0.19$ (−0.54, 0.15)   | $-11.1±13.5$                             |
| Dyspnoea (0–10 Borg scale)      | $0.23$ (−0.12, 0.58)   | $-0.08$ (−0.14, −0.01)  | $-2.2±2.6$                               |
| Leg exertion (0–10 Borg scale)  | $0.55$ (0.15, 0.95)    | $-0.06$ (−0.14, 0.02)   | $-2.2±3.3$                               |

Data are presented as mean differences (95% CI). The mean differences of all outcomes were calculated with two different linear regression models (Model 1: adjusting for the experimental condition, sequence period and subject; Model 2: adjusting for the experimental condition, knee angle, sequence period and subject). The analysis of heart rate data was performed with 46 subjects. Limits of agreement of mean differences in the two experimental conditions (1MSTSIND and 1MSTSSTD) (1.96×SD). STS: sit-to-stand; SpO2: oxygen saturation.

![Figure 3](https://doi.org/10.1183/23120541.00033-2022)

**FIGURE 3** Bland–Altman plot: difference (in repetitions) in the two experimental conditions. Solid lines: mean difference of repetitions; dashed lines: limits of agreement (1.96×SD); circles: representation of participants; 1MSTSSTD: 1 min sit-to-stand test performed on 46 cm height chair; 1MSTSIND: 1 min sit-to-stand test performed on chair adapted to 90° knee flexion.
There were three participants who had a difference in STS repetitions outside the limits of agreement (figure 3). Of those, two participants with a knee angle of 72° and 82° on 1MSTSSTD performed six and eight repetitions more than on the 7.2 cm and 5.5 cm lower 1MSTSIND, respectively, and one participant with a knee flexion angle of 93° on 1MSTSSTD performed six repetitions more on the 2.2 cm higher 1MSTSIND.

Figure S3 (see online supplementary material) gives an overview of the mean differences for the different knee flexion angles. We did not find a significant difference for a specific knee angle.

Incorrectly performed STS repetitions
Seventeen (34.7%) participants performed at least one and a maximum of three STS repetitions incorrectly. Four participants performed more incorrect STS repetitions on 1MSTSSTD, and 11 performed more incorrect STS repetitions on 1MSTSIND.

Among those 11 participants, the seat height of the 1MSTSIND was lower than 1MSTSSTD in two participants it was higher, and in another two participants the seat height was 46 cm in both testing conditions (no adjustment needed as per study protocol).

STS power index
The STSPOWER — calculated with Model 1 — was not different between 1MSTSIND compared to 1MSTSSTD (0.05 Watts (95% CI −2.74 to 2.64)). In addition, the interaction term (Model 2) was not statistically significant: −0.23 (95% CI −0.76 to 0.30); see table 2.

Oxygen saturation, heart rate, and perceived dyspnoea and leg exertion
Post-test heart rate data were available for 46 (94%) participants. In three individuals, measurement artefacts were noted, and heart rate data had to be discarded. Nadir SpO2, post-test heart rate and perceived dyspnoea were no different between experimental conditions.

Perceived post-test leg exertion was 0.55 (95% CI 0.15 to 0.95) units higher on 1MSTSIND compared to 1MSTSSTD. The interaction term in Model 2 did not show a significant effect for leg exertion: −0.06 (95% CI −0.14 to 0.02); see table 2.

Self-administered questionnaire
All participants reported having understood the instructions of the 1MSTS test. Among 49 participants: 40 (82%) participants reported no need for adaptation of seat height when the test was performed on a standard chair (1MSTSSTD); 27% of participants who performed the 1MSTS with a lower seat height (1MSTSIND) preferred to raise the seat height; 18% of participants who performed both 1MSTS tests on the standard height chair preferred to raise the seat height; 50% of participants who performed the test with a higher seat height (1MSTSIND) reported to prefer to raise the seat height.

The participants reported the following reasons for preferring to perform the test on a higher seat height: “shorter distance to cover” (n=9), “less exhausting” (n=8), “more comfortable” (n=2), “easier to perform” (n=6).

Discussion
This randomised crossover study investigated the impact of an individually adjusted seat height on 1MSTS test performance compared with a commonly used seat height in people with COPD. We observed fewer repetitions and higher self-reported leg exertion on the individually adjusted seat height compared to the standard seat height. No differences between the two experimental conditions were observed in STSPOWER, subjective perception of dyspnoea or nadir SpO2.

Primary outcome: 1MSTS test performance
This study revealed a statistically significant difference between 1MSTSIND compared with 1MSTSSTD. However, the mean difference (95% CI) of −0.78 repetitions (95% CI −1.47 to −0.11) is negligible when interpreted on a study population level.

Our study sample included participants with a knee flexion angle of 72°–96° when sitting on the standard chair, resulting in an individual seat height ranging from 37.5 cm to 50.1 cm. We observed that a smaller knee angle (i.e. lower individual chair height) seems to result in fewer repetitions on 1MSTSIND compared to 1MSTSSTD, whereas a larger knee angle (i.e. higher individual chair height), seems to result in more repetitions on 1MSTSIND compared to 1MSTSSTD. Of note, the significant interaction term in Model 2 should not be overinterpreted. The mean difference of 0.78 repetitions is statistically significant, but...
probably not relevant for clinical practice. Notably, three of 49 individuals had a difference in STS repetitions outside the limits of agreement, as seen in figure 3. However, among those individuals, there was no clear association between difference in STS performance and body height, leg length or knee angle. Because our cohort did not include a sufficient number of very tall or short individuals, further studies may be necessary to determine whether adaptation of seat height is required to ensure a valid assessment of 1MSTSTest performance in people with chronic disease.

**Secondary outcomes**

In our study, participants reported significantly higher subjective leg exertion on 1MSTSSND compared to 1MSTSSTD (mean difference 0.55, 95% CI 0.15 to 0.95). **Yamada and Demura** [14] have shown that standing up from the seated position is more difficult for people with a more flexed lower leg. That means using a lower seat height increases the distance that a person must cover to perform the STS movement, thus increasing leg muscle activity [14]. This may have resulted in a higher subjective perception of leg muscle exertion in our study with little impact on overall 1MSTSTest performance on a study population level. Interestingly, during an STS task, people with COPD have a longer standing and stand-to-sit phase compared to healthy controls, resulting in lower performance [29]. The latter phase requires eccentric muscle contractions and a high knee extensor muscle activity, which might be one reason for the higher perceived leg exertion during 1MSTSSND compared to 1MSTSSTD. We further evaluated the force-generating capacity of the knee extensor muscles by calculating STSPower, a measure of mechanical power and functional capacity [21, 26]. We found no differences in STSPower between the two experimental conditions. It may well be that the difference in chair heights between the experimental conditions was not large enough to affect mechanical power values. Nevertheless, our observations of higher perceived leg exertion after performing the 1MSTSSND seem to be supported by the participants’ responses in the questionnaires. Among those who reported a desire to change the seat height, upward adjustment was preferred. Other secondary outcomes were not different between experimental conditions.

**Strengths and limitations**

We chose a crossover design in which each participant served as their own control in order to minimise confounding [30]. All assessments and test instructions were done by the same assessor, eliminating inter-rater variability. Moreover, we were able to mask participants as they did not receive details about the different experimental conditions and were not aware of seat height adjustments.

Our trial has limitations. We used the Easy Angle Digital Goniometer to measure knee flexion angles of the participants. The measurement is possible with a standard error of 1.15°. Furthermore, the participants were not aware of seat height adjustments and were not asked if they wanted to change the height. Moreover, we were able to mask participants as they did not receive details about the experimental conditions.

**Conclusions**

We found that individuals with chronic respiratory disease had a higher 1MSTSTest performance compared to healthy controls. Moreover, we found that a greater range of knee angles was performed in our study compared to a study by Kuo [28]. Furthermore, participants in the study by Kuo [28] had better health status and performed as many repetitions during an STS task as their own control. Our study has limitations. We used the Easy Angle Digital Goniometer to measure knee flexion angles of the participants. The measurement is possible with a standard error of 1.15°. Moreover, we were able to mask participants as they did not receive details about the experimental conditions. Nevertheless, in our study, we found that participants reported significantly higher subjective leg exertion on 1MSTSSND compared to 1MSTSSTD (mean difference 0.55, 95% CI 0.15 to 0.95). Yamada and Demura [14] have shown that standing up from the seated position is more difficult for people with a more flexed lower leg. That means using a lower seat height increases the distance that a person must cover to perform the STS movement, thus increasing leg muscle activity [14]. This may have resulted in a higher subjective perception of leg muscle exertion in our study with little impact on overall 1MSTSTest performance on a study population level. Interestingly, during an STS task, people with COPD have a longer standing and stand-to-sit phase compared to healthy controls, resulting in lower performance [29]. The latter phase requires eccentric muscle contractions and a high knee extensor muscle activity, which might be one reason for the higher perceived leg exertion during 1MSTSSND compared to 1MSTSSTD. We further evaluated the force-generating capacity of the knee extensor muscles by calculating STSPower, a measure of mechanical power and functional capacity [21, 26]. We found no differences in STSPower between the two experimental conditions. It may well be that the difference in chair heights between the experimental conditions was not large enough to affect mechanical power values. Nevertheless, our observations of higher perceived leg exertion after performing the 1MSTSSND seem to be supported by the participants’ responses in the questionnaires. Among those who reported a desire to change the seat height, upward adjustment was preferred. Other secondary outcomes were not different between experimental conditions.
and exchange with other pulmonary rehabilitation centres across Switzerland, a chair height of 46–48 cm is commonly used. To best mimic current clinical rehabilitation practice, we decided to use a chair with 46 cm height as the standard chair. It is important to note that the generalisability of our findings to other chronic disease populations might be limited, in particular for populations with a larger distribution of relatively smaller or taller persons.

In conclusion, our data suggest no clinically relevant difference in 1MSTS performance between the use of an individually adjusted versus standard chair in people with COPD when interpreted on a group level.

Provenance: Submitted article, peer reviewed.

This study is registered at www.ClinicalTrials.gov identifier number NCT04579055.

Data availability: Our dataset has been deposited with Dryad (https://doi.org/10.5061/dryad.z8w9ghxfq).

Conflict of interest: None declared.

References

1 Spruit MA, Pitta F, Garvey C, et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. *Eur Respir J* 2014; 43: 1326–1337.

2 Vaidya T, Chambellan A, de Bisschop C. Sit-to-stand tests for COPD: a literature review. *Respir Med* 2017; 128: 70–77.

3 Bohannon RW, Crouch R. 1-minute sit-to-stand test: systematic review of procedures, performance, and clinimetric properties. *J Cardiopulm Rehabil Prev* 2019; 39: 2–8.

4 Crook S, Büsching G, Schultz K, et al. A multicentre validation of the 1-min sit-to-stand test in patients with COPD. *Eur Respir J* 2017; 49: 1601871.

5 Puhan MA, Siebeling L, Zoller M, et al. Simple functional performance tests and mortality in COPD. *Eur Respir J* 2013; 42: 956–963.

6 Vaidya T, de Bisschop C, Beaumont M, et al. Is the 1-minute sit-to-stand test a good tool for the evaluation of the impact of pulmonary rehabilitation? Determination of the minimal important difference in COPD. *Int J Chron Obstruct Pulmon Dis* 2016; 11: 2609–2616.

7 Ozalevli S, Ozden A, Itil O, et al. Comparison of the sit-to-stand test with 6 min walk test in patients with chronic obstructive pulmonary disease. *Respir Med* 2007; 101: 286–293.

8 van Gestel AJR, Clarenbach CF, Stöwhas AC, et al. Predicting daily physical activity in patients with chronic obstructive pulmonary disease. *PloS One* 2012; 7: e48081.

9 Zanini A, Aiello M, Cherubino F, et al. The one repetition maximum test and the sit-to-stand test in the assessment of a specific pulmonary rehabilitation program on peripheral muscle strength in COPD patients. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 2423–2430.

10 Fernandes AL, Neves I, Luis G, et al. Is the 1-minute sit-to-stand test a good tool to evaluate exertional oxygen desaturation in chronic obstructive pulmonary disease? *Diagnostics (Basel)* 2021; 11: 159.

11 Yoshioka S, Nagano A, Hay DC, et al. Peak hip and knee joint moments during a sit-to-stand movement are invariant to the change of seat height within the range of low to normal seat height. *Biomed Eng Online* 2014; 13: 27.

12 Chorin F, Rahmani A, Beaune B, et al. Determination of reliable force platform parameters and number of trial to evaluate sit-to-stand movement. *Aging Clin Exp Res* 2015; 27: 473–482.

13 Hughes MA, Weiner DK, Schenkenman ML, et al. Chair rise strategies in the elderly. *Clin Biomech* 1994; 9: 187–192.

14 Yamada T, Demura S. Influence of the relative difference in chair seat height according to different lower thigh length on floor reaction force and lower-limb strength during sit-to-stand movement. *J Physiol Anthropol Appl Human Sci* 2004; 23: 197–203.

15 Janssen WG, Bussmann HB, Stam HJ. Determinants of the sit-to-stand movement: a review. *Phys Ther* 2002; 82: 866–879.

16 Demura S, Yamada T. Height of chair seat and movement characteristics in sit-to-stand by young and elderly adults. *Percept Mot Skills* 2007; 104: 21–31.

17 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40: 1324–1343.

18 Miller MR, Quanjer PH, Swanney MP, et al. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. *Chest* 2011; 139: 52–59.

19 Paterick TJ, Carson GV, Allen MC, et al. Medical informed consent: general considerations for physicians. *Mayo Clin Proc* 2008; 83: 313–319.

20 Snow G. blockrand: Randomization for Block Random Clinical Trials. www.cran.r-project.org/web/packages/blockrand/index.html Date last accessed: 22 July 2022.
21 Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
22 Takai Y, Ohta M, Akagi R, et al. Sit-to-stand test to evaluate knee extensor muscle size and strength in the elderly: a novel approach. J Physiol Anthropol 2009; 28: 123–128.
23 Svensson M, Lind V, Löfgren Harringe M. Measurement of knee joint range of motion with a digital goniometer: a reliability study. Physiother Res Int 2019; 24: e1765.
24 Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health 1990; 16 Suppl 1: 55–58.
25 Senn S. Cross-over Trials in Clinical Research. Chichester, John Wiley & Sons, Ltd, 2002; p. 343.
26 Bland JM, Altman D. Statistical methods for assessing agreement between two methods for clinical measurement. Lancet 1986; 327: 307–310.
27 Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8: 135–160.
28 Kuo YL. The influence of chair seat height on the performance of community-dwelling older adults’ 30-second chair stand test. Aging Clin Exp Res 2013; 25: 305–309.
29 Janssens L, Brumagne S, McConnell AK, et al. Impaired postural control reduces sit-to-stand-to-sit performance in individuals with chronic obstructive pulmonary disease. PLoS One 2014; 9: e88247.
30 Sedgwick P. Bias in randomised controlled trials: comparison of crossover group and parallel group designs. BMJ 2015; 351: h4283.
31 Radtke T, Hebestreit H, Puhan MA, et al. The 1-min sit-to-stand test in cystic fibrosis – insights into cardiorespiratory responses. J Cyst Fibros 2017; 16: 744–751.
32 Kohlbrenner D, Benden C, Radtke T. The 1-minute sit-to-stand test in lung transplant candidates: an alternative to the 6-minute walk test. Respir Care 2020; 65: 437–443.
33 Strassmann A, Steurer-Stey C, Lana KD, et al. Population-based reference values for the 1-min sit-to-stand test. Int J Public Health 2013; 58: 949–953.